Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication June 7, 2018
- Accepted for publication July 21, 2018
- Published online March 1, 2019.
Article Versions
- previous version (August 2, 2018 - 13:54).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2019 by the Society of Nuclear Medicine and Molecular Imaging. Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml.
Author Information
- Frederik L. Giesel*,1,
- Clemens Kratochwil*,1,
- Thomas Lindner1,
- Manfred M. Marschalek1,
- Anastasia Loktev1,
- Wencke Lehnert2,
- Jürgen Debus3,4,
- Dirk Jäger5,
- Paul Flechsig1,
- Annette Altmann1,
- Walter Mier1 and
- Uwe Haberkorn1,6,7
- 1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg Germany
- 2ABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaft m.b.H, Dresden, Germany
- 3Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany
- 4Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany
- 5Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany
- 6Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany; and
- 7Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany
- For correspondence or reprints contact: Uwe Haberkorn, Department of Nuclear Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany. E-mail: uwe.haberkorn{at}med.uni-heidelberg.de
↵* Contributed equally to this work.
Statistics from Altmetric.com
Cited By...
Article usage
Jump to section
Related Articles
Cited By...
- SNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET
- FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study
- Fibroblast Activation Protein-Directed Imaging Outperforms 18F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial
- 68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy
- 68Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18F-FDG
- A Systematic Review on the Diagnostic Value of Fibroblast Activation Protein Inhibitor PET/CT in Genitourinary Cancers
- 68Ga-FAPI PET/CT as an Alternative to 18F-FDG PET/CT in the Imaging of Invasive Lobular Breast Carcinoma
- Diagnostic Accuracy of 68Ga-FAPI Versus 18F-FDG PET in Patients with Various Malignancies
- Design, Preclinical Evaluation, and Clinical Translation of 68Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma
- Fibroblast Activation Protein-Targeted PET/CT with 18F-Fibroblast Activation Protein Inhibitor-74 for Evaluation of Gastrointestinal Cancer: Comparison with 18F-FDG PET/CT
- 68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial
- Performance of 68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT in Evaluation of Erdheim-Chester Disease: A Comparison with 18F-FDG PET/CT
- Initial Evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions
- Clinical Evaluation of 68Ga-FAPI-RGD for Imaging of Fibroblast Activation Protein and Integrin {alpha}v{beta}3 in Various Cancer Types
- Tumor Characterization by [68Ga]FAPI-46 PET/CT Can Improve Treatment Selection for Pancreatic Cancer Patients: An Interim Analysis of a Prospective Clinical Trial
- Initial Evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions
- 68Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study
- Clinical Evaluation of 68Ga-FAPI-RGD for Imaging of Fibroblast Activation Protein and Integrin {alpha}v{beta}3 in Various Cancer Types
- Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities
- Biodistribution, Dosimetry, and Pharmacokinetics of 68Ga-CBP8: A Type I Collagen-Targeted PET Probe
- Three-Time-Point PET Analysis of 68Ga-FAPI-46 in a Variety of Cancers
- Staging Liver Fibrosis by Fibroblast Activation Protein Inhibitor PET in a Human-Sized Swine Model
- Dual-Tracer PET/CT Protocol with [18F]-FDG and [68Ga]Ga-FAPI-46 for Cancer Imaging: A Proof of Concept
- Pitfalls and Common Findings in 68Ga-FAPI PET: A Pictorial Analysis
- Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of 68Ga-Labeled FAPI Dimer
- Biology of Cancer and PET Imaging: Pictorial Review
- Initial Clinical Experience with 90Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients
- 68Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the 68Ga-FAPI PET Prospective Observational Trial
- 68Ga-DOTA-FAPI-04 PET/MR in the Evaluation of Gastric Carcinomas: Comparison with 18F-FDG PET/CT
- Fibroblast Activation Protein-Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study
- The Annual Journal Impact Factor Saga
- Impact of 68Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas
- First Experience Using 18F-Flubrobenguane PET Imaging in Patients with Suspected Pheochromocytoma or Paraganglioma
- FAPI PET/CT: Will It End the Hegemony of 18F-FDG in Oncology?
- FAPI-74 PET/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients
- The Latest Developments in Imaging of Fibroblast Activation Protein
- Fibroblast Activation Protein-Targeted PET/CT with 68Ga-FAPI for Imaging IgG4-Related Disease: Comparison to 18F-FDG PET/CT
- Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy
- Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an 18F-Labeled FAP Inhibitor
- Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging
- Design and Development of 99mTc-Labeled FAPI Tracers for SPECT Imaging and 188Re Therapy
- The Role of 68Ga-FAPI PET/CT for Patients with Malignancies of the Lower Gastrointestinal Tract: First Clinical Experience
- Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients
- The Future of Nuclear Medicine Depends on the Quality of Its Research: Researchers at the University of Heidelberg Receive the Award for Best Article of the Year
- Reversibility of 68Ga-FAPI-2 Trapping Might Prove an Asset for PET Quantitative Imaging
- Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: 64Cu- and 225Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models
- FAP: The Next Billion Dollar Nuclear Theranostics Target?
- A Conversation Between Uwe Haberkorn and Johannes Czernin
- Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention
- The Future of Nuclear Medicine as an Independent Specialty
- Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine
- Photoacoustic imaging as a tool to probe the tumour microenvironment
- 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer